Note
This is not the latest version of the data and there is another version of this page. Other versions of this page:
The Pf6 Web Resource accompanies a detailed scientific manuscript which describes in detail the complete processes and methods used to determine inferred phenotypes presented here. To access this information, please visit https://www.malariagen.net/resource/26.
Further to that manuscript, this web resource visualizes the 6th version of the “MalariaGEN P. falciparum Community Project” which includes for the first time a set of phenotype predictions based on genetic molecular markers. In these pages we show individual and summary information on anti-malarial drug resistance to:
- Artemisinin
- Chloroquine
- Mefloquine
- Piperaquine
- Pyrimethamine
- Sulfadoxine
Additionally, we estimate Rapid Diagnostic Test (RDT) failure by looking at genomic deletions of the associated genes Histidine-Rich Protein 2 (PfHRP2) and Histidine-Rich Protein 3 (PfHRP3).
For the estimation of drug resistance, we focus on the following molecular markers for each drug described.
Artemisinin: Pf3D71343700; _PfKelch13 – WHO classified resistance mutation within codons 349 - 726
Chloroquine: PF3D70709000; _PfCRT – Codon 76
Mefloquine: PF3D70523000; _PfMDR1 – whole gene amplification status
Piperaquine: Pf3D71408000 & Pf3D7_1408100; _Pfplasmepsin2 & 3 – gene amplification status of both genes
Pyrimethamine: PF3D70417200; _PfDHFR – Codon 108
Sulfadoxine: PF3D70810800; _PfDHPS – Codon 437